MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.800
-0.020 (-1.10%)
At close: Feb 9, 2026, 4:00 PM EST
1.790
-0.010 (-0.56%)
After-hours: Feb 9, 2026, 4:04 PM EST
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,801,778
Market Cap
5.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 9 | 1 | 12.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | 7 | -5 | -41.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 57 |
| Calidi Biotherapeutics | 28 |
| VivoSim Labs | 13 |
| Processa Pharmaceuticals | 10 |
| Purple Biotech | 9 |
| Mustang Bio | 6 |
| Quoin Pharmaceuticals | 5 |
| Can-Fite BioPharma | 5 |
MTVA News
- 5 days ago - MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel - PRNewsWire
- 24 days ago - MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option - PRNewsWire
- 25 days ago - MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering - PRNewsWire
- 5 weeks ago - MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile - PRNewsWire
- 6 weeks ago - MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference - PRNewsWire
- 7 weeks ago - MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 2 months ago - MetaVia Inc. Announces 1-for-11 Reverse Stock Split - PRNewsWire
- 3 months ago - MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025 - PRNewsWire